Add to Basket Bulk discount
Order hotline:
+1 404 474 4654
+1 888 205 9894 (TF)

C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1) (pTyr276) Peptide

Name

C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1)
Synonyms ABL, JTK7, p150, c-ABL, v-abl, bcr/abl, Abl, c-Abl, AI325092, MGC117749, E430008G22Rik, ABL1, ARG, ABLL, FLJ22224, FLJ31718, FLJ41441, Arg, Abll, AA536808, MGC169395, ABL2, CABL, cb272
Binding Site

pTyr276
5 references available
Certificates ISO 9001:2008
Catalog no. ABIN693933
Quantity 0.1 mg
Price 49.50 $   Plus shipping costs $45.00
Bulk discount
Shipping to
Availability Will be delivered in 2 to 3 Business Days

Additional Information
Application Details Publications Alternatives back to top

Immunogen Synthetic peptide
Characteristics Blocking peptide for Phospho-ABL1-Y276 antibody ABIN389505
Specificity The synthetic peptide sequence used to generate the antibody AP3016a was selected from the region of human Phospho-ABL1-Y276. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Comments

Background: ABL1 is a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. The t(9,22) translocation results in the head-to-tail fusion of the BCR and ABL1 genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for ABL1.

Application Details
Publications Alternatives back to top

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Restrictions For Research Use only

Publications
Application Details Alternatives back to top

Product Aichberger, Mayerhofer, Krauth et al.: "Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides." in: Blood, Vol. 105, Issue 8, pp. 3303-11, 2005 (PubMed).

Wei, Li, Liu: "Insights into selective activation of p53 DNA binding by c-Abl." in: The Journal of biological chemistry, Vol. 280, Issue 13, pp. 12271-8, 2005 (PubMed).

Robinson, Martineau, Harris et al.: "Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 19, Issue 4, pp. 564-71, 2005 (PubMed).

Kim, Cho, Yoon et al.: "Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra signal-FISH." in: Genes, chromosomes & cancer, Vol. 43, Issue 1, pp. 37-44, 2005 (PubMed).

Barnes, McIntosh, Whetton et al.: "Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation." in: Oncogene, Vol. 24, Issue 20, pp. 3257-67, 2005 (PubMed).

Alternatives
Application Details Publications back to top

Alternatives for antigen "C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1)", type "Peptides"
Reactivities Mouse (Murine) (11), Human (10), Rat (Rattus) (6)